Scholarlink

Introduction <p>Ruxolitinib cream has demonstrated efficacy and safety in patients aged ≥ 2&#xa0;years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated that initiation of ruxolitinib cream may reduce the need for other AD therapies, both topical and systemic. This analysis investigated the longer-term (18-month) effect of ruxolitinib cream on AD treatment patterns.</p> Methods <p>In this retrospective, observational study, US claims data from the Healthcare Integrated Research Database (HIRD<sup>®</sup>) were used to identify new ruxolitinib cream users aged ≥ 12&#xa0;years between October 1, 2021 and July 31, 2022. The 6&#xa0;months prior to the index date (first claim for ruxolitinib cream) comprised the baseline period. The 18-month follow-up period was divided into months&#xa0;1–6, 7–12, and 13–18 to evaluate short- and long-term effects of ruxolitinib cream on AD treatment patterns.</p> Results <p>A total of 1269 patients were included in the analysis. The mean (SD; range) number of ruxolitinib cream fills during the 18-month follow-up period was 2.4 (2.3; 1–19). By months&#xa0;13–18 of follow-up, claims for topical corticosteroids, topical calcineurin inhibitors, and topical PDE4 inhibitors were reduced from baseline by 52%, 63%, and 70%, respectively. Use of oral corticosteroids was reduced by 28%, with a 32% reduction in the mean cumulative prednisone-equivalent dose. Among patients with baseline biologic AD therapy (<i>n</i> = 231), 35.5% did not receive biologics during months&#xa0;13–18 of follow-up. Additionally, among patients without baseline biologic use (<i>n</i> = 1038), &gt; 90% remained off biologics.</p> Conclusion <p>Use of both topical and systemic AD therapies, including biologics, decreased over 18&#xa0;months following initiation of ruxolitinib cream. These data suggest that ruxolitinib cream may reduce the need for additional topical therapies and limit escalation to systemic therapies for adults and adolescents with AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Jinan Liu,
  • Karishma Desai,
  • Chia-Chen Teng,
  • Peter Chen,
  • Vincent Willey,
  • Daniel Sturm

摘要

Introduction

Ruxolitinib cream has demonstrated efficacy and safety in patients aged ≥ 2 years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated that initiation of ruxolitinib cream may reduce the need for other AD therapies, both topical and systemic. This analysis investigated the longer-term (18-month) effect of ruxolitinib cream on AD treatment patterns.

Methods

In this retrospective, observational study, US claims data from the Healthcare Integrated Research Database (HIRD®) were used to identify new ruxolitinib cream users aged ≥ 12 years between October 1, 2021 and July 31, 2022. The 6 months prior to the index date (first claim for ruxolitinib cream) comprised the baseline period. The 18-month follow-up period was divided into months 1–6, 7–12, and 13–18 to evaluate short- and long-term effects of ruxolitinib cream on AD treatment patterns.

Results

A total of 1269 patients were included in the analysis. The mean (SD; range) number of ruxolitinib cream fills during the 18-month follow-up period was 2.4 (2.3; 1–19). By months 13–18 of follow-up, claims for topical corticosteroids, topical calcineurin inhibitors, and topical PDE4 inhibitors were reduced from baseline by 52%, 63%, and 70%, respectively. Use of oral corticosteroids was reduced by 28%, with a 32% reduction in the mean cumulative prednisone-equivalent dose. Among patients with baseline biologic AD therapy (n = 231), 35.5% did not receive biologics during months 13–18 of follow-up. Additionally, among patients without baseline biologic use (n = 1038), > 90% remained off biologics.

Conclusion

Use of both topical and systemic AD therapies, including biologics, decreased over 18 months following initiation of ruxolitinib cream. These data suggest that ruxolitinib cream may reduce the need for additional topical therapies and limit escalation to systemic therapies for adults and adolescents with AD.